指南与共识糖尿病

加拿大糖尿病指南传播策略对血管保护药物处方的影响:2010-2015年回顾性队列研究

Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010-2015.
指南 / 共识 · Diabetes Care · 2018-11-02

该研究基于加拿大初级保健哨点监测网络(CPCSSN)中≥40岁2型糖尿病患者数据,采用中断时间序列分析评估2013年加拿大糖尿病指南发布及传播工具对处方他汀、ACEI/ARB或抗血小板药物的影响。结果显示指南发布后他汀(每季度-0.52%,SE 0.15,P<0.05)、ACEI/ARB(每季度-0.38%,SE 0.13,P<0.05)及参照药PPI(每季度-0.18%,SE 0.05,P<0.05)的处方率斜率均显著下降,但下降趋势并非血管保护药物特有。结论认为需要更有效的知识转化策略以改善糖尿病患者的血管保护。

要点

  • 2013年加拿大糖尿病指南发布后,他汀和ACEI/ARB处方率斜率显著下降,但参照药PPI也下降,趋势非血管保护药特有。
  • 指南发布时(基线)他汀、ACEI/ARB、抗血小板及PPI处方率均无显著变化(P值分别为0.43、0.42、0.39、0.16)。
  • 需更有效的知识转化策略以改善糖尿病患者血管保护药物的处方。

核心结论

  • 指南发布后血管保护药物处方趋势下降,但该下降并非血管保护药物特有,需更有效的知识转化策略。

研究设计与样本

  • 采用中断时间序列分析评估每季度符合条件患者中他汀、ACEI/ARB或抗血小板处方的比例,以质子泵抑制剂(PPI)处方为参照对照。
  • 动态队列每季度入组,每季度样本量范围为25,985至70,693例。

主要发现

  • 指南发布时(基线)他汀(P=0.43)、ACEI/ARB(P=0.42)、抗血小板(P=0.39)及PPI(P=0.16)处方率均无显著变化。
  • 指南发布后,他汀处方率斜率显著变化(每季度-0.52%,SE 0.15,P<0.05)。
  • 指南发布后,ACEI/ARB处方率斜率显著变化(每季度-0.38%,SE 0.13,P<0.05)。
  • 指南发布后,参照药PPI处方率斜率亦显著变化(每季度-0.18%,SE 0.05,P<0.05)。

临床怎么用

  • 应关注指南传播策略的实际效果,单纯发布指南及传播工具可能不足以改善血管保护药物的处方趋势。
  • 临床中需结合更有效的知识转化策略(如针对性反馈、教育外展等)以促进糖尿病患者血管保护药物的合理使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The 2013 Diabetes Canada guidelines launched targeted dissemination tools and a simple assessment for vascular protection. We aimed to 1) examine changes associated with the launch of the 2013 guidelines and additional dissemination efforts in the rates of vascular protective medications prescribed in primary care for older patients with diabetes and 2) examine differences in the rates of prescriptions of vascular protective medications by patient and provider characteristics. RESEARCH DESIGN AND METHODS: The study population included patients (≥40 years of age) from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) with type 2 diabetes and at least one clinic visit from April 2010 to December 2015. An interrupted time series analysis was used to assess the proportion of eligible patients prescribed a statin, ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB), or antiplatelet prescription in each quarter. Proton pump inhibitor (PPI) prescriptions were the reference control. RESULTS: A dynamic cohort was used where participants were enrolled each quarter using a prespecified set of conditions (range 25,985-70,693 per quarter). There were no significant changes in statin (P = 0.43), ACEI/ARB (P = 0.42), antiplatelet (P = 0.39), or PPI (P = 0.16) prescriptions at baseline (guideline intervention). After guideline publication, there was a significant change in slope for statin (-0.52% per quarter, SE 0.15, P < 0.05), ACEI/ARB (-0.38% per quarter, SE 0.13, P < 0.05), and reference PPI (-0.18% per quarter, SE 0.05, P < 0.05) prescriptions. CONCLUSIONS: There was a decrease in prescribing trends over time that was not specific to vascular protective medications. More effective knowledge translation strategies are needed to improve vascular protection in diabetes in order for patients to receive the most effective interventions.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rigobon AV, Kalia S, Nichols J, et al. Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010-2015. Diabetes Care. 2018. PMID: 30389671. doi:10.2337/dc18-0935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。